Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22451370 | 0.94 | LTA4H (0.61) | NQO1MAPTGAAESR2TSHR | |
| 1-Methoxy-4-Ethoxybenzene SCHEMBL354674 | 0.93 | NQO1 (0.78) | NQO1MAPTGAATSHRTDP1 | |
| SCHEMBL18417193 | 0.90 | NQO1 (0.82) | NQO1GAATSHRTDP1KDM4E | |
| SCHEMBL5833291 | 0.90 | NQO1 (0.82) | NQO1GAATSHRTDP1KDM4E | |
| SCHEMBL9155582 | 0.90 | NQO1 (0.82) | NQO1GAATSHRTDP1KDM4E | |
| SCHEMBL19339337 | 0.86 | LTA4H (0.68) | NQO1MAPTGAATSHRTDP1 | |
| SCHEMBL13048467 | 0.83 | NQO1 (0.70) | NQO1GAATSHRTDP1KDM4E | |
| SCHEMBL22788361 | 0.82 | NQO1 (0.50) | NQO1MAPTGAATDP1ESR1 | |
| SCHEMBL8944288 | 0.82 | NQO1 (0.61) | NQO1MAPTGAATSHRTDP1 | |
| SCHEMBL11671912 | 0.82 | LTA4H (0.63) | NQO1MAPTGAATSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570317-A2 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | Intervet International B.V. (NL) | 2025-06-18 | — | — | EP | disclosed |
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | INTERVET INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-12157717-B2 | Compounds for the treatment of bovine or swine respiratory disease | INTERVET INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-12077488-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | INTERVET INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| WO-2024033418-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | BACOBA AG (CH) | 2024-02-15 | — | — | WO | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| CN-116829524-A | Method for alkylating acidic functional groups | 中外制药株式会社 | 2023-09-29 | — | — | CN | disclosed |
| CN-110072844-B | Compounds for the treatment of infection by Mannheimia haemolytica or histophilus somni | 英特维特国际股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2004111058-A1 | HETERORYL-FUSED PYRIMIDINYL COMPOUNDS AS ANTICANCER AGENTS | CHIRON CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | UNIVERSITY OF WASHINGTON | 2004-11-18 | — | — | US | disclosed |
| WO-2004092360-A2 | THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | CHIRON CORPORATION (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2004-09-09 | — | — | US | disclosed |
| WO-2004062601-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
| WO-2004048365-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | NQO1 1475/4885MAPT 3948/4885GAA 1389/4885 |
| US-12077488-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | SORD, HEXD, SNRPD1 | NQO1 162/4885MAPT 3738/4885GAA 314/4885 |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | NQO1 1475/4885MAPT 3981/4885GAA 1340/4885 |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | PDF, DDOST, MRPL21 | NQO1 2517/4885MAPT 3822/4885GAA 55/4885 |
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | SORD, HEXD, SNRPD1 | NQO1 263/4885MAPT 4017/4885GAA 566/4885 |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | PI4KB, PI4KA, PDPK1 | NQO1 2964/4885MAPT 1941/4885GAA 799/4885 |
| US-12157717-B2 | Compounds for the treatment of bovine or swine respiratory disease | PIGS, BTD, PPARD | NQO1 362/4885MAPT 2194/4885GAA 361/4885 |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | NQO1 323/4885MAPT 4829/4885GAA 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.